Ivacaftor deuterated

Drug Profile

Ivacaftor deuterated

Alternative Names: C-10355; C-10358; CTP-656; D-ivacaftor; Deuterated ivacaftor

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Concert Pharmaceuticals
  • Class Amides; Aminophenols; Organic deuterium compounds; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 08 Aug 2017 Chemical structure information added
  • 25 Jul 2017 Vertex Pharmaceuticals purchases ivacaftor deuterated from Concert Pharmaceuticals
  • 24 Jul 2017 Concert Pharmaceuticals terminates HSR Act Waiting Period for ivacaftor deuterated asset purchase agreement with Vertex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top